Responses
Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release
Compose a Response to This Article
Other responses
No responses have been published for this article.
